1
0
0
News
VAXIMM kündigt Präsentationen auf wissenschaftlichen Kongressen und...
www.pressebox.de
VAXIMM GmbH, Die VAXIMM AG, ein schweizerisch/deutsches Biotechnologieunternehmen, das auf die Entwicklung oraler T-Zell-Immuntherapi…
Dr. Heinz Lubenau Archive - GoingPublic.de
www.goingpublic.de
Dr. Heinz Lubenau Oktober 23, Über uns. Kontaktieren Sie uns: . Folgen Sie uns. MEDIADATEN GOING PUBLIC MAGAZIN ...
DGAP-News: VAXIMM AG: VAXIMM kündigt Präsentationen bei Konferenzen...
www.finanznachrichten.de
Heinz Lubenau wird eine Unternehmenspräsentation geben. Details zur Präsentation werden nach Bekanntgabe auf der Webseite von VAXIMM veröffentlicht.
Heinz Lubenau - akampion
www.akampion.com
“We are very encouraged by these data,” added Dr. Heinz Lubenau, General Manager of VAXIMM GmbH, a fully owned subsidiary of VAXIMM AG in Germany. “It provides a strong basis for continuing the development of VXM01 for the treatment of solid tumor diseases. Following regulatory approval, we ...
Netzwerk-Profile
LinkedIn: Heinz Lubenau | LinkedIn
Heinz Lubenaus berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Heinz Lubenau dabei hilft, ...
LinkedIn: Heinz Lubenau | LinkedIn
Heinz Lubenau hat 9 Jobs im Profil angegeben. Sehen Sie sich auf LinkedIn das vollständige Profil an und erfahren Sie mehr über die Kontakte von Heinz Lubenau und über Jobs bei ähnlichen Unternehmen VAXIMM. Früher. VAXIMM,; BioGeneriX AG,; Servier Forschung und Pharmaentwicklung GmbH. Ausbildung.
Ontbrekend: sap
Heinz Lubenau Vaximm GmbH [LSE] Life-Sciences-Europe.com - The...
www.life-sciences-europe.com
Life Sciences Business Intelligence Web Portal for European countries
Interessen
NEC und VAXIMM kündigen Zusammenarbeit an, um ...
www.businesswire.com
— Dr. Heinz Lubenau, Chief Operating Officer und Mitbegründer von VAXIMM, sagte: „Wir freuen uns, diese Allianz mit NEC einzugehen und die ... › news › home
Heinz Lubenau - Patents
www.freshpatents.com
Recent bibliographic sampling of Heinz Lubenau patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title):
Neoantigen Targeted Therapies Market,
www.prnewswire.com
— Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM) All actual figures have been sourced and analyzed from publicly available ... › neo...
Management & Beteiligungen
Vaximm AG in Basel - Auskünfte | Moneyhouse
www.moneyhouse.ch
Vaximm AG in Basel ✓ aktiv ✓ Gegründet ✓ Management: Prof. Dr. Dr. Tomas Dezsö Szucs u.a ✓ Letzte Änderung: ✓
Business-Profile
Xing: Heinz Lubenau
Dr. / Chief Operating Officer / Mannheim / diabetes, Drug development and project management expertise, transition to clinical first-in-human trials, cardiology, national and European Scientific Advice experience, and hypertension., biosimilar development background
patentbuddy: Heinz Lubenau
BIOGENERIX AG, Neustadt, DE
Thomas D. Szucs (BB Biotech AG)Life-Sciences-Europe.com
www.life-sciences-europe.com
Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ... Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ...
Firmen-Mitarbeiter
VAXIMM company portrait | VAXIMM
vaximm.com
Management Team VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise. Supervisory
VAXIMM company portrait
vaximm.com
Dr. Heinz Lubenau hat VAXIMM im Jahr mitgegründet Im Jahr begann er bei Servier und übernahm die Funktion des Clinical Research Manager und ... › ueber-uns
Private Homepages
About 14ᵗʰ ELSF - Sachs Eventssachsevent.com
sachsevent.com
... Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting.
Impressum | VAXIMM
vaximm.com
VAXIMM AG Technologiepark Basel . CH Basel Schweiz. Verwaltungsratspräsident: Dr. Thomas Hecht. VAXIMM GmbH. MAFINEX-Technologiezentrum Mannheim Deutschland. Geschäftsführer: Dr. Heinz Lubenau. . HRB
Besitz
US DNA vaccine for use in pancreatic cancer patients
patentscope.wipo.int
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections....
Búsqueda en las colecciones de patentes nacionales e ...WIPO - Search International and National Patent Collections
patentscope.wipo.int
... Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic ...
Bücher
Full article: ProfileTaylor & Francis Online
www.tandfonline.com
von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ... von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ...
heiBIB: Leowardi-Bauer, Christine
katalog.ub.uni-heidelberg.de
... Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M. Breiner, Gerd Mikus ...
Dokumente zum Namen
Abstract B196: Live attenuated oral Salmonella platform for ...aacrjournals.org
aacrjournals.org
von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar. von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar.
AbstractAmerican Society of Clinical Oncology
meetings.asco.org
... Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany ...
AbstractAmerican Society of Clinical Oncology (ASCO)
meetings.asco.org
... Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip ...
Wissenschaftliche Veröffentlichungen
US Patent Application for NOVEL MSLN TARGETING DNA VACCINE FOR CANCER...
patents.justia.com
Filed: Oct 17, Publication Date: Mar 8, Inventors: Marco SPRINGER (Wendlingen), Heinz LUBENAU (Neustadt an der Weinstrasse)
GlycoPEGylated Filgrastim XM22 Demonstrates Dose ...ScienceDirect.com
www.sciencedirect.com
von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ... von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ...
Double-blind, placebo-controlled first in human study to ...BMC Cancer
bmccancer.biomedcentral.com
von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ... von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ...
Patents Assigned to Ratiopharm GmbHJustia
patents.justia.com
Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ... Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ...
Veröffentlichungen allgemein
pdfSpringer
link.springer.com
von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany
Questionaire for VAXIMM: Interview with Dr. Klaus Breiner, Executive...
www.biomedsearch.com
Questionaire for VAXIMM: Interview with Dr. Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager. MedLine Citation:.
Questionaire for VAXIMM: Interview with Dr. Klaus Breiner ...ResearchGate
www.researchgate.net
— Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September — Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September
Double-blind, placebo-controlled first in human study to investigate...
link.springer.com
... contains supplementary material, which is available to authorized users. Andreas G Niethammer, Heinz Lubenau contributed equally to this work.
Artikel & Meinungen
BIOTECH IN EUROPE FORUM - PDF Free Download
businessdocbox.com
22 VAXIMM AG HEINZ LUBENAU COO Heinz Lubenau co-founded VAXIMM in and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to thishe was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, ...
12th ANNUAL EUROPEAN LIFE SCIENCES CEO FORUMGenSearch
www.gensearch-consulting.com
— Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital — Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital ...
Vaximm is using AI to develop cancer vaccinesBasel Area Business & Innovation
baselarea.swiss
— Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the — Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the ...
Sonstiges
Heinz Lubenau | LinkedIn
www.linkedin.com
View Heinz Lubenau's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Heinz Lubenau discover ...
Heinz Lubenau's PostLinkedIn · Heinz Lubenau120+ Reaktionen · vor 1 Jahr
www.linkedin.com
Heinz Lubenau, our CEO and co-founder, will give a company ... Heinz Lubenau, our CEO, will give a company presentation and be part of the ... Heinz Lubenau, our CEO and co-founder, will give a company ... Heinz Lubenau, our CEO, will give a company presentation and be part of the ...
Method for producing high yield attenuated Salmonella strains
patents.google.com
... Inventor: Heinz Lubenau: Holger Siede: Renate Janssen: Marco Springer; Current Assignee (The listed assignees may be inaccurate. › patent
VAXIMM initiates Phase 2a study in advanced Yahoo Finance
uk.finance.yahoo.com
"We have seen encouraging data in several preclinical colorectal cancer models," said Dr. Heinz Lubenau, VAXIMM's Chief Operating Officer and General Manager of VAXIMM GmbH. "The results from this new clinical trial will be important in adding to our knowledge base and guiding the development of ...
Dr. Heinz Lubenau ArchivesMedtech Alert
medtechalert.com
Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ... Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ...
NEC OncoImmunity Acquires VAXIMM's Neoantigen ...Yahoo Finance
finance.yahoo.com
— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...
VAXIMM startet eine Phase-2a-Studie mit dem oral Yahoo Finanzen
de.finance.yahoo.com
Dr. Heinz Lubenau, COO und Geschäftsführer der VAXIMM GmbH, kommentierte: "Wir haben in verschiedenen präklinischen ...
Heinz Lubenau - Chief Drug Development OfficerThe Org
theorg.com
Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ... Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ...
Heinz Lubenau Email Address & Phone NumberAeroLeads
aeroleads.com
Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority. Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority.
Clinical Studies for Oral Cancer Vaccine
www.process-worldwide.com
Vaxxim, a Merck business, begins clinical studies for a new oral cancer vaccine. The drug is the first of its kind, the company states, targeting not the tumor...
2022 Expert-Speaker Faculty - Neoantigen Summit Europe
neoantigen-europe.com
Nouscom Srl. Heinrich Haas. Vice President Formulation and Drug Development. BioNTech AG. Heinz Lubenau. Chief Executive Officer & Co-Founder. Vaximm GmbH ... › 2...
6th Neoantigen Summit Europeinicop
www.inicop.org
... Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of ...
GSCF BIT Congress
www.bitcongress.com
Dr. Heinz Lubenau, CEO, Vaximm AG, Germany, Dr. Thomas Justel, Professor, FH Munster University of Applied Sciences, Germany, Dr. Yves Rozenholc, ... › gscf...
Advancing Cancer Vaccines to Move to the Forefront of ...Allucent
www.allucent.com
Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ... Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ...
Altmetric – Anti-angiogenic activity of VXM01, an oral T-cell vaccine...
www.altmetric.com
... Friedrich H Schmitz-Winnenthal, Nicolas Hohmann, Andreas G Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M Breiner, Gerd Mikus, ...
VAXIMM Starts Clinical Study of First Oral Cancer Vaccine, VAXIMM...
www.pressebox.com
VAXIMM GmbH, VAXIMM AG, a Swiss-German biotech firm and Merck KGaA spin-off, announced today the start of the first clinical trial of…
Double-blind, placebo-controlled first in human study to ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ... von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ...
Pharmacokinetic and pharmacodynamic profile of new Gale
go.gale.com
von H Lubenau · · Zitiert von: 73 — Dr Heinz Lubenau and Anne-Katrin Maly are employees of BioGeneriX AG, Mannheim, Germany. Dr Peter Bias is an employee of Merckle GmbH, Ulm, Germany, ... › i.do
sortiert nach Relevanz / Datum